Sugi Predict

Sugi Predict / Compounds / Formic Acid

Formic Acid

Formic Acid

SCHEMBL3473883

CO.Cc1ccc(C(Cl)Cl)cc1.O=CO

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 1/20 0.39
▸ LMNA P02545 7/20 0.38
▸ ALDH1A1 P00352 6/20 0.38
▸ SMN1; SMN2 Q16637 5/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ TSHR P16473 1/20 0.37
▸ STAT3 P40763 1/20 0.37
▸ CHRNA7 P36544 1/20 0.37
▸ ACHE P22303 2/20 0.36
▸ ALOX5 P09917 1/20 0.36
▸ PKM P14618 2/20 0.35
▸ HTT P42858 2/20 0.35
▸ ATM Q13315 2/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ HPGD P15428 2/20 0.35
▸ TDP1 Q9NUW8 2/20 0.35
▸ NLRP1 Q9C000 1/20 0.35
▸ NTSR1 P30989 1/20 0.35
▸ CES2 O00748 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL330031 0.83 ACHE (0.50) LMNAALDH1A1SMN1; SMN2MEN1KMT2A
Acetic Acid SCHEMBL10769278 0.80 LMNA (0.46) LMNAALDH1A1SMN1; SMN2MEN1KMT2A
P-Xylene SCHEMBL5241939 0.78 CYP2A6 (0.58) CYP2A6LMNAALDH1A1SMN1; SMN2MEN1
Methylene Chloride SCHEMBL10711029 0.77 TSHR (0.43) LMNAALDH1A1SMN1; SMN2MEN1KMT2A
P-Xylene SCHEMBL28001011 0.75 CYP2A6 (0.55) CYP2A6LMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL10757547 0.73 CYP2A6 (0.42) CYP2A6LMNAALDH1A1SMN1; SMN2MEN1
Formic Acid SCHEMBL28075217 0.72 CES2 (0.60) CYP2A6LMNAALDH1A1SMN1; SMN2MEN1
Hexane SCHEMBL11219188 0.71 HTT (0.42) LMNAALDH1A1SMN1; SMN2TSHRCHRNA7
Ethyl Acetate SCHEMBL4531538 0.71 LMNA (0.50) LMNAALDH1A1SMN1; SMN2MEN1KMT2A
Formic Acid SCHEMBL30236894 0.71 PTGS2 (0.55) LMNAALDH1A1SMN1; SMN2TSHRSTAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048654-A1 USE OF VALSARTAN OR ITS METABOLITE TO IN HIBIT PLATELET AGGREGATION NOVARTIS PHARMACEUTICALS CORPORATION 2010-02-25 — — US disclosed
EP-1505965-B1 USE OF THE METABOLITE OF VALSARTAN TO INHIBIT PLATELET AGGREGATION NOVARTIS AG (CH) 2006-08-02 — — EP disclosed
US-20050197372-A1 Use of valsartan or its metabolite to inhibit platelet aggregation MALININ ALEX (US) 2005-09-08 — — US disclosed
EP-1505965-A1 USE OF VALSARTAN OT ITS METABOLITE TO INHIBIT PLATELET AGGREGATION Novartis AG (CH) 2005-02-16 — — EP disclosed
WO-2003094915-A1 USE OF VALSARTAN OT ITS METABOLITE TO INHIBIT PLATELET AGGREGATION NOVARTIS AG (CH) 2003-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048654-A1 USE OF VALSARTAN OR ITS METABOLITE TO IN HIBIT PLATELET AGGREGATION PDGFRA, PLAT, PTAFR CYP2A6 348/4885LMNA 3758/4885ALDH1A1 796/4885
US-20050197372-A1 Use of valsartan or its metabolite to inhibit platelet aggregation PTAFR, PDGFRA, ACE CYP2A6 333/4885LMNA 3943/4885ALDH1A1 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.